Port REMoval Outcomes (PREMO) study: Patients' experiences with a Totally Implantable Venous Access Device: A questionnaire at device removal.

IF 1.6 3区 医学 Q3 PERIPHERAL VASCULAR DISEASE
Godelieve Alice Goossens, Thomas Douchy, Martine Jérôme, Yorick Peeters, Daphne Hompes, Veerle Boecxstaens
{"title":"Port REMoval Outcomes (PREMO) study: Patients' experiences with a Totally Implantable Venous Access Device: A questionnaire at device removal.","authors":"Godelieve Alice Goossens, Thomas Douchy, Martine Jérôme, Yorick Peeters, Daphne Hompes, Veerle Boecxstaens","doi":"10.1177/11297298251340461","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Totally Implantable Venous Access Devices (TIVADs) are commonly used for intravenous chemotherapy administration and may remain in place depending on the likelihood of disease relapse. Regular flushing is required to maintain patency, although there is no established consensus on the optimal interval between maintenance sessions, with some clinicians extending or omitting the procedure. While TIVADs are generally well-accepted, patients may experience physical discomfort or psychological stress, which are assessed through Patient Reported Outcomes (PROs). This study aims to evaluate the complete TIVAD experience, from insertion to removal, with a particular focus on the maintenance period, as part of the Port REMoval Outcomes (PREMO) study.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted at University Hospitals Leuven, Belgium between 2019 and 2022. Adult patients with chest TIVADs, planned for an elective removal, completed the Leuven Patient Reported Experiences at Port Removal (Leuven PREP) a self-reported, self-developed 27-item questionnaire.</p><p><strong>Results: </strong>A total of 100 oncology patients completed the questionnaire, with a mean age of 60.9 years and a median TIVAD duration of 2093 days. Most patients reported low insertion pain (median NRS score = 2), while emotional and psychological impacts were generally minimal, with only 1% expressing constant fear. Local discomfort was mentioned, with 24.5% reporting a bump and 12% experiencing pain during needle insertion; 10% experienced frequent cosmetic issues. TIVAD maintenance adherence was limited to 70.7% following the flushing regimen, and 61.2% found extending the maintenance period valuable. The removal procedure was well-received, with 60.2% reporting it was better than expected, and overall patient satisfaction was high, with a median score of 8/10.</p><p><strong>Conclusion: </strong>Patients expressed high satisfaction with low impact on comfort, psychological state and physical well-being. Maintenance experiences varied, highlighting the need for further investigation and a validated comprehensive questionnaire.</p><p><strong>Registration number: </strong>NCT03948958.</p>","PeriodicalId":56113,"journal":{"name":"Journal of Vascular Access","volume":" ","pages":"11297298251340461"},"PeriodicalIF":1.6000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vascular Access","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11297298251340461","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Totally Implantable Venous Access Devices (TIVADs) are commonly used for intravenous chemotherapy administration and may remain in place depending on the likelihood of disease relapse. Regular flushing is required to maintain patency, although there is no established consensus on the optimal interval between maintenance sessions, with some clinicians extending or omitting the procedure. While TIVADs are generally well-accepted, patients may experience physical discomfort or psychological stress, which are assessed through Patient Reported Outcomes (PROs). This study aims to evaluate the complete TIVAD experience, from insertion to removal, with a particular focus on the maintenance period, as part of the Port REMoval Outcomes (PREMO) study.

Methods: A cross-sectional survey was conducted at University Hospitals Leuven, Belgium between 2019 and 2022. Adult patients with chest TIVADs, planned for an elective removal, completed the Leuven Patient Reported Experiences at Port Removal (Leuven PREP) a self-reported, self-developed 27-item questionnaire.

Results: A total of 100 oncology patients completed the questionnaire, with a mean age of 60.9 years and a median TIVAD duration of 2093 days. Most patients reported low insertion pain (median NRS score = 2), while emotional and psychological impacts were generally minimal, with only 1% expressing constant fear. Local discomfort was mentioned, with 24.5% reporting a bump and 12% experiencing pain during needle insertion; 10% experienced frequent cosmetic issues. TIVAD maintenance adherence was limited to 70.7% following the flushing regimen, and 61.2% found extending the maintenance period valuable. The removal procedure was well-received, with 60.2% reporting it was better than expected, and overall patient satisfaction was high, with a median score of 8/10.

Conclusion: Patients expressed high satisfaction with low impact on comfort, psychological state and physical well-being. Maintenance experiences varied, highlighting the need for further investigation and a validated comprehensive questionnaire.

Registration number: NCT03948958.

端口移除结果(PREMO)研究:患者使用完全植入式静脉通路装置的经验:一份关于设备移除的问卷。
背景:全植入式静脉通路装置(TIVADs)通常用于静脉化疗给药,并可根据疾病复发的可能性保留原位。定期冲洗是维持通畅的必要条件,尽管对于维持时间的最佳间隔没有建立共识,一些临床医生延长或省略了该程序。虽然tivad被普遍接受,但患者可能会感到身体不适或心理压力,这是通过患者报告的结果(PROs)来评估的。本研究旨在评估完整的TIVAD体验,从插入到移除,特别关注维护期,作为端口移除结果(PREMO)研究的一部分。方法:2019 - 2022年在比利时鲁汶大学医院进行横断面调查。计划择期取出胸部tivad的成年患者完成了鲁汶患者Port removal experience (Leuven PREP),这是一份自我报告、自行开发的27项问卷。结果:共100例肿瘤患者完成问卷,平均年龄60.9岁,中位TIVAD持续时间2093天。大多数患者报告低插入痛(NRS评分中位数= 2),而情绪和心理影响通常很小,只有1%的患者表示持续的恐惧。提到局部不适,24.5%的人报告肿块,12%的人在针头插入时感到疼痛;10%的人经常出现美容问题。冲洗方案后,TIVAD维持依从性限制在70.7%,61.2%的人认为延长维持期是有价值的。移除手术效果良好,60.2%的患者报告比预期的要好,总体患者满意度很高,中位得分为8/10。结论:患者满意度高,对舒适度、心理状态和身体健康影响小。维护经验各不相同,强调需要进一步调查和验证全面的问卷调查。注册号:NCT03948958。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Vascular Access
Journal of Vascular Access 医学-外周血管病
CiteScore
3.40
自引率
31.60%
发文量
181
审稿时长
6-12 weeks
期刊介绍: The Journal of Vascular Access (JVA) is issued six times per year; it considers the publication of original manuscripts dealing with clinical and laboratory investigations in the fast growing field of vascular access. In addition reviews, case reports and clinical trials are welcome, as well as papers dedicated to more practical aspects covering new devices and techniques. All contributions, coming from all over the world, undergo the peer-review process. The Journal of Vascular Access is divided into independent sections, each led by Editors of the highest scientific level: • Dialysis • Oncology • Interventional radiology • Nutrition • Nursing • Intensive care Correspondence related to published papers is also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信